Foghorn Therapeutics (FHTX) to Release Quarterly Earnings on Tuesday

Foghorn Therapeutics (NASDAQ:FHTX) will be releasing its earnings data on Tuesday, April 9th.

Foghorn Therapeutics (NASDAQ:FHTX) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.22. The company had revenue of $5.77 million for the quarter, compared to the consensus estimate of $4.91 million. On average, analysts expect Foghorn Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Foghorn Therapeutics Price Performance

Shares of FHTX opened at $7.10 on Monday. Foghorn Therapeutics has a 1-year low of $2.70 and a 1-year high of $9.97. The company has a 50-day moving average of $6.03 and a 200 day moving average of $5.09. The firm has a market capitalization of $302.25 million, a price-to-earnings ratio of -3.03 and a beta of 3.13.

Institutional Investors Weigh In On Foghorn Therapeutics

Hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC lifted its position in shares of Foghorn Therapeutics by 92.0% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,687 shares of the company’s stock worth $31,000 after purchasing an additional 1,767 shares during the period. UBS Group AG purchased a new stake in shares of Foghorn Therapeutics in the 4th quarter worth approximately $32,000. Wells Fargo & Company MN lifted its position in Foghorn Therapeutics by 1,368.4% during the fourth quarter. Wells Fargo & Company MN now owns 5,389 shares of the company’s stock valued at $34,000 after acquiring an additional 5,022 shares during the last quarter. Barclays PLC lifted its position in Foghorn Therapeutics by 533.5% during the fourth quarter. Barclays PLC now owns 5,397 shares of the company’s stock valued at $34,000 after acquiring an additional 4,545 shares during the last quarter. Finally, Citigroup Inc. lifted its position in Foghorn Therapeutics by 1,321.0% during the second quarter. Citigroup Inc. now owns 6,778 shares of the company’s stock valued at $48,000 after acquiring an additional 6,301 shares during the last quarter. Hedge funds and other institutional investors own 61.55% of the company’s stock.

About Foghorn Therapeutics

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.